The iTind procedure is an alternative to daily BPH medication or invasive surgery. If patients do not want to take a pill every day, or if they have tried standard drug treatments and were unsatisfied with the level of symptomatic relief or the way they made them feel. The iTind procedure might also be the right choice if patients are interested in preserving their sexual function and continence, are worried about having a permanent implant, or are concerned about undergoing a surgery that would involve a long recovery and downtime.

Most patients start to experience symptom relief shortly after the removal. Symptoms typically continue to improve over the following 6 to 12 weeks. In clinical studies there have been no indications of long-term adverse side effects. Since the iTind device is completely removed at the end of the 5-7 day indwelling period, there is no risk of implant migration, encrustation, or tissue overgrowth. Moreover, there are no obstacles in maintaining a regular prostate screening program, including physical exams or any type of imaging, such as MRI, if needed.

The most common side effects experienced are the feeling of pressure in the area of the perineum, an increased frequency and urgency to urinate, light blood in urine, and slight burning upon urination. However, any side effects experienced typically subside shortly after the iTind device is removed. After insertion of the iTind device, patients may be kept for a few hours for observation. Upon returning home they may resume most normal activities depending on their personal level of comfort and their doctor’s advice. You can read more about our Patient Management information contained within our iTind Procedure Guide (PDF, 7.0 MB).

Durability has been demonstrated in clinical studies out to 6.6 years in terms of symptom improvement, urinary flow and quality of life in a significant number of patients. The iTind procedure does not preclude retreatment or other BPH treatments, should they be needed or desired in the future. The iTind procedure leaves nothing behind. You can read more about the clinical data here (PDF, 7.0 MB).